Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108,380,780
-
Total 13F shares
-
24,251,145
-
Share change
-
-2,893,844
-
Total reported value
-
$62,327,000
-
Price per share
-
$2.57
-
Number of holders
-
50
-
Value change
-
-$3,890,419
-
Number of buys
-
16
-
Number of sells
-
27
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q3 2020
As of 30 Sep 2020 Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) had 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 24,251,145 shares of stock of the company.
Largest 10 holders included RENAISSANCE TECHNOLOGIES LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Samsara BioCapital, LLC, Rock Springs Capital Management LP, Sofinnova Investments, Inc., Parkman Healthcare Partners LLC, Vivo Capital, LLC, EcoR1 Capital, LLC, Endurant Capital Management LP, and BlackRock Inc..
This table shows 50 institutional shareholders of the security as of 30 Sep 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.